{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035655","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.686908+00:00","generated_at":"2026-06-04T08:28:21.120238+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint in Phase 3 SYMPHONY Trial for Narcolepsy","bullets":["AXS-12 reduced weekly cataplexy attacks by 83% vs 66% for placebo (p=0.018) at Week 5.","Cataplexy remission achieved by 33% of AXS-12 patients vs 9.5% placebo (p=0.008).","Excessive daytime sleepiness severity reduced (CGI-S p=0.027) and cognitive function improved (p=0.004).","Concurrent EDS and cataplexy response in 57% of AXS-12 patients vs 33% placebo (p=0.029)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035655","json":"https://secwatch.observer/filing/0000950170-24-035655.json","markdown":"https://secwatch.observer/filing/0000950170-24-035655.md","text":"https://secwatch.observer/filing/0000950170-24-035655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/0000950170-24-035655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/axsm-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:28:21.120238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}